PE20210473A1 - Derivados de gip y usos de estos - Google Patents

Derivados de gip y usos de estos

Info

Publication number
PE20210473A1
PE20210473A1 PE2020001751A PE2020001751A PE20210473A1 PE 20210473 A1 PE20210473 A1 PE 20210473A1 PE 2020001751 A PE2020001751 A PE 2020001751A PE 2020001751 A PE2020001751 A PE 2020001751A PE 20210473 A1 PE20210473 A1 PE 20210473A1
Authority
PE
Peru
Prior art keywords
gip
relates
peptides
derivatives
nash
Prior art date
Application number
PE2020001751A
Other languages
English (en)
Inventor
Wouter Frederik Johan Hogendorf
Henning Thøgersen
Nicholas Raymond Cox
Patrick J Knerr
Richard Dimarchi
Brian Finan
Jesper F Lau
Steffen Reedtz-Runge
Fa Liu
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of PE20210473A1 publication Critical patent/PE20210473A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/645—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2235—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

La presente invencion se refiere a peptidos novedosos que son derivados de analogos del polipeptido insulinotropico dependiente de la glucosa (GIP) que tienen una estabilidad fisica mejorada en solucion y un perfil de accion prolongado. Mas en particular, la invencion se refiere a dichos peptidos que son agonistas del receptor de GIP y a su uso en el control del peso o para el tratamiento de enfermedades tales como la obesidad, la diabetes o la esteatohepatitis no alcoholica (NASH).
PE2020001751A 2018-05-04 2019-05-03 Derivados de gip y usos de estos PE20210473A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862666916P 2018-05-04 2018-05-04
EP18172827 2018-05-17
PCT/EP2019/061413 WO2019211451A1 (en) 2018-05-04 2019-05-03 Gip derivatives and uses thereof

Publications (1)

Publication Number Publication Date
PE20210473A1 true PE20210473A1 (es) 2021-03-08

Family

ID=66440040

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020001751A PE20210473A1 (es) 2018-05-04 2019-05-03 Derivados de gip y usos de estos

Country Status (20)

Country Link
US (2) US10604555B2 (es)
EP (1) EP3788063B1 (es)
JP (2) JP6818940B2 (es)
KR (1) KR102379958B1 (es)
CN (1) CN112074531A (es)
AU (1) AU2019263674B2 (es)
BR (1) BR112020022027A2 (es)
CA (1) CA3097939A1 (es)
CL (1) CL2020002796A1 (es)
CO (1) CO2020014180A2 (es)
ES (1) ES2961384T3 (es)
IL (1) IL278171A (es)
MA (1) MA52483A (es)
MX (1) MX2020011427A (es)
PE (1) PE20210473A1 (es)
PH (1) PH12020551742A1 (es)
RU (1) RU2020136305A (es)
SG (1) SG11202010297UA (es)
TW (1) TWI707865B (es)
WO (1) WO2019211451A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109923114B (zh) 2016-09-09 2022-11-01 因赛特公司 作为hpk1调节剂的吡唑并吡啶衍生物和其用于治疗癌症的用途
AR109595A1 (es) 2016-09-09 2018-12-26 Incyte Corp Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1
US20180072718A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine compounds and uses thereof
MX2020008656A (es) 2018-02-20 2020-12-09 Incyte Corp Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores de la cinasa de progenitores hematopoyeticos 1 (hpk1) para tratar el cancer.
US10752635B2 (en) 2018-02-20 2020-08-25 Incyte Corporation Indazole compounds and uses thereof
US10604555B2 (en) * 2018-05-04 2020-03-31 Novo Nordisk A/S GIP derivatives and uses thereof
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
KR20220059480A (ko) 2019-08-06 2022-05-10 인사이트 코포레이션 고체 형태의 hpk1 억제제
MX2022011089A (es) 2020-03-06 2022-10-03 Sanofi Sa Peptidos como agonistas selectivos del receptor de gip.
WO2021198229A1 (en) 2020-03-31 2021-10-07 Antaros Medical Ab Selective gip receptor agonists comprising a chelating moiety for imaging and therapy purposes
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
EP4185607A1 (en) 2020-07-22 2023-05-31 Novo Nordisk A/S Co-agonists at glp-1 and gip receptors suitable for oral delivery
KR20230106616A (ko) * 2020-11-09 2023-07-13 엠바크 바이오테크 에이피에스 타키키닌 수용체 매개 장애의 치료에 있어서의 화합물 및 이의 용도
WO2022270956A1 (ko) 2021-06-23 2022-12-29 주식회사 펩트론 세마글루타이드 또는 이의 약학적으로 허용가능한 염을 포함하는 서방형 제제 조성물
AU2022339059A1 (en) 2021-09-06 2024-05-02 Sanofi New peptides as potent and selective gip receptor agonists
WO2023118263A1 (en) * 2021-12-21 2023-06-29 Embark Biotech Aps Agonists for treatment of eating disorder
TW202330584A (zh) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途
WO2023151594A1 (en) * 2022-02-11 2023-08-17 Hangzhou Sciwind Biosciences Co., Ltd. A composition comprising gip receptor agonists and glp-1 receptor agonists and use thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1171465T3 (da) 1999-03-29 2004-12-13 Uutech Ltd Analoger til gastroinhibitorisk peptid og deres anvendelse til behandling af diabetes
GB0404124D0 (en) * 2004-02-25 2004-03-31 Univ Ulster Antagonists of GIP
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
PE20100056A1 (es) 2008-06-17 2010-01-26 Univ Indiana Res & Tech Corp Analogos de glucagon como agonistas gip
CN102171243A (zh) 2008-08-07 2011-08-31 益普生制药股份有限公司 N-端修饰的葡萄糖依赖性促胰岛素多肽(gip)类似物
CN103641906A (zh) 2008-08-07 2014-03-19 益普生制药股份有限公司 葡萄糖依赖性促胰岛素多肽类似物
EP2915538A3 (en) 2008-08-07 2015-10-14 Ipsen Pharma S.A.S. Truncated analogues of glucose-dependent insulinotropic polypeptide
EP2328922A4 (en) 2008-08-07 2013-01-02 Ipsen Pharma Sas ANALOGUE OF GLUCOSE-DEPENDING INSULINOTROPIC POLYPEPTIDE
JP6006118B2 (ja) * 2009-12-16 2016-10-12 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アナログ及び誘導体
JP2013518115A (ja) 2010-01-27 2013-05-20 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション 代謝疾患及び肥満の治療のためのグルカゴンアンタゴニスト‐ｇｉｐアゴニスト複合体及び組成物
CA2797089A1 (en) 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
BR112012028704A2 (pt) 2010-05-13 2019-09-24 Univ Indiana Res & Tech Corp composto de glugagon da superfamília de peptídeos exibindo atividade do receptor com hormônio nuclear, pró fármaco, dímero ou multímero, composição farmacêutica que o compreendem e método de administração do mesmo.
US9249181B2 (en) * 2010-09-13 2016-02-02 Amylin Pharmaceuticals, Llc C-terminal amidation of polypeptides
US9023986B2 (en) 2010-10-25 2015-05-05 Hoffmann-La Roche Inc. Glucose-dependent insulinotropic peptide analogs
EP2654774A4 (en) 2010-12-22 2015-07-01 Marcadia Biotech Inc METHOD FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS WITH GIP AND GLP-1 RECEPTOR ACTIVE PUCIDIDES ON GLUCAGON BASIS
CN103764673A (zh) * 2011-06-10 2014-04-30 北京韩美药品有限公司 葡萄糖依赖性促胰岛素多肽类似物、其药物组合物及应用
US20130090285A1 (en) 2011-06-27 2013-04-11 Phasebio Pharmaceuticals, Inc. Methods of treatment with glp-1 receptor agonists
US10100097B2 (en) * 2012-05-03 2018-10-16 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
TWI644920B (zh) 2012-06-21 2018-12-21 美商印第安納大學科技研究公司 展現ｇｉｐ受體活性之胰高血糖素類似物
US20160024169A1 (en) 2013-03-14 2016-01-28 Indiana University Research And Technology Corporation Insulin-incretin conjugates
CN105307672B (zh) 2013-04-18 2021-01-05 诺和诺德股份有限公司 用于医学用途的稳定、延长的glp-1/胰高血糖素受体共激动剂
AU2014272500B2 (en) 2013-05-28 2018-03-08 Scohia Pharma, Inc. Peptide compound
US10266577B2 (en) 2013-08-15 2019-04-23 Novo Nordisk A/S GLP-1 derivatives, and uses thereof
WO2015022420A1 (en) 2013-08-16 2015-02-19 Medimmune Limited Gip and glp-1 receptor dual-agonists for the treatment of diabetes
WO2015067716A1 (en) 2013-11-06 2015-05-14 Zealand Pharma A/S Glucagon-glp-1-gip triple agonist compounds
TWI670281B (zh) 2013-11-06 2019-09-01 西蘭製藥公司 Ｇｉｐ－ｇｌｐ－１雙重促效劑化合物及方法
EP3151852A1 (en) * 2014-06-04 2017-04-12 Novo Nordisk A/S Glp-1/glucagon receptor co-agonists for medical use
EP3189072B1 (en) 2014-09-05 2018-07-18 University of Copenhagen Gip peptide analogues
MX2017005457A (es) * 2014-10-29 2017-07-04 Zealand Pharma As Metodos y compuestos agonistas de gip.
ES2739289T3 (es) * 2014-11-27 2020-01-30 Novo Nordisk As Derivados de GLP-1 y sus usos
JOP20200119A1 (ar) * 2015-01-09 2017-06-16 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
EP3262041A4 (en) 2015-02-27 2018-08-01 Lycera Corporation Indazolyl thiadiazolamines and related compounds for inhibition of rho-associated protein kinase and the treatment of disease
US20190000928A1 (en) 2015-06-17 2019-01-03 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
US20190175744A1 (en) 2016-03-18 2019-06-13 Merck Sharp & Dohme Corp. Insulin-incretin conjugates
WO2017210168A1 (en) 2016-06-02 2017-12-07 Indiana University Research And Technology Corporation Aqueously soluble and chemically stable depsi glucagon agonists
EP4361173A2 (en) * 2017-05-31 2024-05-01 University of Copenhagen Long-acting gip peptide analogues
US10604555B2 (en) * 2018-05-04 2020-03-31 Novo Nordisk A/S GIP derivatives and uses thereof

Also Published As

Publication number Publication date
US10604555B2 (en) 2020-03-31
EP3788063B1 (en) 2023-08-09
EP3788063C0 (en) 2023-08-09
WO2019211451A1 (en) 2019-11-07
ES2961384T3 (es) 2024-03-11
TW202003550A (zh) 2020-01-16
BR112020022027A2 (pt) 2021-02-02
AU2019263674A1 (en) 2020-11-26
US11633459B2 (en) 2023-04-25
TWI707865B (zh) 2020-10-21
CO2020014180A2 (es) 2021-01-29
KR102379958B1 (ko) 2022-04-01
MX2020011427A (es) 2020-12-07
US20190367578A1 (en) 2019-12-05
KR20210005700A (ko) 2021-01-14
RU2020136305A (ru) 2022-05-05
CA3097939A1 (en) 2019-11-07
PH12020551742A1 (en) 2021-06-28
AU2019263674B2 (en) 2023-03-02
IL278171A (en) 2020-11-30
JP6818940B2 (ja) 2021-01-27
CL2020002796A1 (es) 2021-02-19
EP3788063A1 (en) 2021-03-10
SG11202010297UA (en) 2020-11-27
MA52483A (fr) 2021-03-10
CN112074531A (zh) 2020-12-11
US20220000982A1 (en) 2022-01-06
JP2020125311A (ja) 2020-08-20
JP2020528925A (ja) 2020-10-01

Similar Documents

Publication Publication Date Title
PE20210473A1 (es) Derivados de gip y usos de estos
CY1122539T1 (el) Αναλογα γλυκαγονης
CO7400885A2 (es) Análogos de glucagón
CY1121462T1 (el) Ακυλιωμενα αναλογα γλυκαγονης
CO2018002060A2 (es) Compuestos farmacéuticos
PE20210162A1 (es) Analogos de incretina y sus usos
MX2017012864A (es) Analogo acilado del glucagon.
BR112018073511A2 (pt) polipeptídeos seletivos do receptor de glucagon e métodos de uso dos mesmos
CL2014003421A1 (es) Análogos de glucagón que exhiben actividad agonista en el receptor del péptido insulinotrópico dependiente de glusosa (gip): composición farmacéutica; y método para reducir el aumento de peso o inducir pérdida de peso, particularmente para el tratamiento de la obesidad.
ECSP12011593A (es) Análogos de glucagón acilados
CL2019001683A1 (es) Antagonistas de miostatina, activina o receptor de activina para el uso en el tratamiento de la obesidad y afecciones relacionadas.
ECSP12012357A (es) Análogos del glucagón
UY35548A (es) Péptidos terapéuticos para el tratamiento de trastornos metabólicos.
CR11562A (es) Bis-piridilpiridonas como antagonistas del receptor 1 de la hormona concentradora de melanina
PE20170088A1 (es) Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos
ECSP19057403A (es) Usos terapéuticos de un polvo de insectos
PE20171243A1 (es) Composicion de liberacion modificada de orlistat y acarbosa para el tratamiento de la obesidad y trastornos metabolicos relacionados
CL2020000812A1 (es) Semaglutida en la terapia médica.
ECSP15009391A (es) siARN Y SU USO EN LOS MÉTODOS Y COMPOSICIONES PARA EL TRATAMIENTO Y/O PREVENCIÓN DE ENFERMEDADES DE LOS OJOS
CO2020002500A2 (es) Análogos de insulina acilados novedosos y usos de estos
BR112017002206A2 (pt) peptídeo derivado de koc1 e vacina incluindo o mesmo
AR115077A1 (es) Derivados de gip y sus usos
ECSP16094286A (es) Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas
BR112017002212A2 (pt) peptídeo derivado de cdca1 e vacina contendo o mesmo
BR112017002193A2 (pt) peptídeo derivado de urlc10 e vacina contendo o mesmo